| abstract |
A biocompatible alginate biomaterial, which consists of an alginate having a molecular weight between 1,000 and 300,000 Daltons, and said alginate being selected from the group consisting of uncrosslinked alginate and crosslinked alginate with a crosslinking agent selected from the group consisting of calcium, strontium and barium for use in the treatment of impaired liver function in a subject in need, said liver function being altered as a result of fulminant liver failure, hepatectomy and / or liver disease selected from the group consisting of autoimmune hepatitis, chronic hepatitis C and hepatitis Chronic B, in which said treatment comprises the implantation or injection of a framework or a solution of acellular alginate by itself. |